Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication ALIMTA ® is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. FDA label
Also known as NovoTTF-200T, NovoTTF-100L(P), NovoTTF-100L device, NovoTTF-100L, Pemetrexed, Alimta, Electric fields, Optune® device
TTFields · 2 trials · 3 indications
PFS will be measured from the date of enrollment to date of progression (in months) based on RANO citeria.
| Arm | Type | Description |
|---|---|---|
| Experimental: TTFields | EXPERIMENTAL | Patients receive continuous TTFields treatment using the Optune® System with high intensity transducer arrays. |
| A | EXPERIMENTAL | Treatment with concomitant Alimta and NovoTTF-100L |
| Name | Type | Description |
|---|---|---|
| TTFields | DEVICE | TTFields treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine. Other Names: • TTFields |
| NovoTTF-100L | DEVICE | TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing |
Inclusion Criteria: 1. Histologically confirmed diagnosis of GBM according to WHO classification criteria. 2. Age ≥ 18 years 3. Not a candidate for further radiotherapy or additional resection of residual tumor. 4. Patients with first or second radiological disease progression per RANO criteria doc...
TTFields is an investigational oncology therapy being studied for the treatment of Glioblastoma Multiforme (GBM), a type of brain cancer. It is currently in Phase 2 clinical development. The therapy is delivered using the OPTUNE device with high density transducer arrays, as evaluated in a completed pilot study for recurrent GBM.
TTFields is being developed by NovoCure Limited, a company publicly traded under the ticker symbol NVCR. NovoCure is conducting clinical research on this therapy for Glioblastoma Multiforme. The company's development program includes a completed Phase 2 pilot study of the OPTUNE device with high density transducer arrays.
TTFields is in Phase 2 clinical development for Glioblastoma Multiforme. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The therapy is being studied in a completed open-label pilot trial that enrolled 25 patients with recurrent GBM.
TTFields has been studied in one clinical trial, identified as NCT04492163. This was a Phase 2, open-label pilot study titled 'Open-Label Pilot Study of OPTUNE With High Density Transducer Arrays for the Treatment of Recurrent GBM.' The trial was completed and enrolled 25 participants in Czechia.
TTFields is the therapy being investigated, and OPTUNE is the device used to deliver it. In the clinical trial NCT04492163, the treatment involved OPTUNE with high density transducer arrays for recurrent Glioblastoma Multiforme. The trial was an open-label, uncontrolled pilot study that has been completed.